Ofer Sharon, MD, spoke about the PROphet diagnostic platform for non–small cell lung cancer and the latest interim results from the prospective PROPHETIC trial in the most recent episode of CancerNetwork’s® "Oncology Peer Review On-The-Go" podcast.
CancerNetwork® recently spoke with Ofer Sharon, MD, chief executive officer of OncoHost, about interim results from the prospective PROPHETIC trial (NCT04056247) to potentially determine how patients with non–small cell lung cancer (NSCLC) respond to immunotherapy.
Sharon first described the purpose and mission of OncoHost, a clinical stage precision oncology company. Then, he touched on the key details of research being conducted by OncoHost, including the ongoing multicenter PROPHETIC trial, which aimed to assess the PROphet diagnostic platform at the center of this ongoing multicenter clinical trial, as well next steps for this research and OncoHost’s future endeavors.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.